Form 4: Aura Biosciences Director Antony Mattessich Receives Significant Equity Grants

Aura Biosciences, Inc. Director Antony C. Mattessich was granted 13,000 Restricted Stock Units and 17,000 stock options on June 17, 2025, as part of the company's incentive plan.

Summary

• Antony C. Mattessich, a Director of Aura Biosciences, Inc. (AURA), acquired 13,000 shares of common stock through a Restricted Stock Unit (RSU) award on June 17, 2025.
• These RSUs were granted at a price of $0 and will vest in full upon the earlier of June 17, 2026, or the next annual meeting of stockholders, contingent on his continued service.
• Following this transaction, Mr. Mattessich beneficially owns 23,500 shares of common stock directly.
• Additionally, Mr. Mattessich was granted 17,000 stock options on June 17, 2025, with an exercise price of $6.18 per share and an expiration date of June 17, 2035.
• These stock options will vest and become exercisable in full upon the earlier of June 17, 2026, or the next annual meeting of stockholders, also subject to his continued service.
• After this transaction, Mr. Mattessich beneficially owns 17,000 derivative securities (stock options) directly.
• A Power of Attorney was executed on March 28, 2025, appointing Conor Kilroy and Amy Elazzouzi as attorneys-in-fact for filing SEC reports on behalf of Mr. Mattessich.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is generally a positive sign of aligning interests and retaining talent, but it does not contain information that would significantly alter the company's fundamental outlook or financial position.

Positives

• The grant of RSUs and stock options aligns the director's interests with shareholders, incentivizing long-term performance and retention.
• The awards are part of the company's 2021 Stock Option and Incentive Plan, indicating a structured and established approach to executive and director compensation.

Risks

• The vesting of both the RSU award and stock options is subject to the Reporting Person's continued service as of the vesting date, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The document primarily reports past transactions and does not contain explicit forward-looking statements regarding the company's financial performance or strategic direction, beyond the vesting schedule of the equity awards.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors in the biotechnology or pharmaceutical industry, aiming to align their long-term interests with shareholder value. Such grants are common for retaining talent and incentivizing performance in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The grant of Restricted Stock Units and stock options to a director is a common form of equity compensation across publicly traded companies, particularly in the biotech sector.
• The specific amounts (13,000 RSUs and 17,000 options) and the vesting schedule (one year or next annual meeting) are typical for director compensation, designed to incentivize continued service and align interests with long-term company performance.
• Without specific compensation benchmarks for comparable biotech companies of Aura Biosciences' size and stage, a direct quantitative comparison is not feasible from this document alone. However, the structure of the awards is consistent with general industry practices for non-employee director compensation.

Corporate Governance

Related Party Transactions

• The equity grants to a director are a form of related-party transaction, which is standard practice for executive and director compensation within publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vesting of 13,000 RSUs and 17,000 stock options upon the earlier of June 17, 2026, or the next annual meeting of Aura Biosciences' stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Aura Biosciences, AURA, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Director Compensation, Equity Grant, Antony Mattessich, Beneficial Ownership